DiaGen AI and DataMeds AI partner on cancer target discovery
DiaGen AI and Nasdaq-listed DataMeds AI are launching a research partnership to use Helomics’ 70,000-plus tumor biobank to find new cancer targets and develop anticancer peptides and small molecules. The deal gives DiaGen a 630,000-share stake in DataMeds, while both companies plan to share intellectual property from the program.
Why it matters: - The partnership gives DiaGen AI access to one of the world’s largest primary tumor biobanks for cancer target discovery and drug candidate optimization. - The work could speed development of new breast cancer therapies, including for triple negative breast cancer, and broaden to other tumor types if the program identifies a usable mechanism of action. - The agreement also ties each company to the other’s long-term value through a reciprocal equity exchange.
What happened: - DiaGen AI, a Vancouver-based tech-bio company, partnered with DataMeds AI, a Nasdaq-listed healthcare company, to discover novel cancer targets and develop anticancer peptides. - The research program will begin at Helomics, DataMeds’ wholly owned CLIA-certified cancer diagnostics laboratory in Pittsburgh. - DataMeds will issue DiaGen 630,000 common shares, equal to 9.9% of DataMeds common shares outstanding as of the agreement date. - DiaGen will issue DataMeds 9.9% of DiaGen’s fully diluted common shares outstanding in return.
The details: - Helomics’ biobank holds more than 70,000 tumor biopsies, including more than 50,000 gynecologic cancer samples gathered over nearly three decades. - The Helomics Biobank includes primary tumor specimens across GI cancer, brain cancer, breast cancer, head and neck cancer, genitourinary cancer, liver cancer, lung cancer, melanoma, mesothelioma, ovarian cancer, pancreatic cancer, sarcomas and uterine cancer. - Helomics also uses proprietary cell painting and patient-tumor-derived 3D spheroids that preserve tumor stroma and connect to its 2D platform with associated drug-response data. - The companies will first validate 15 cytotoxic peptides identified through DiaGen’s CYPRESS platform and published methodology in Nature Communications. - DiaGen says the peptides already showed in vitro proof of concept in breast cancer cell lines, including triple negative breast cancer, and were at least 5.5 times less toxic to normal human blood cells than to cancer cells in published testing. - The mechanism of action for the DiaGen peptides has not yet been established. - DiaGen and Helomics will work to identify the peptides’ therapeutic target(s), test them on primary breast cancer biopsies and determine whether the same mechanism applies to other cancers in the biobank. - The companies will jointly own intellectual property created from the target-discovery work. - DiaGen will build a library of drug candidates using its BLACKCOMB artificial intelligence small molecule design platform. - Helomics will run preclinical in vitro cell-line and primary-tumor validation to narrow the small molecules for therapeutic development and help confirm candidate selection in breast cancer animal models. - The companies plan to seek pharmaceutical partners or form a joint venture to fund further development. - DataMeds will contribute up to 50% of compute expenses tied to research milestones, primarily from existing compute spend. - DiaGen will cover the cash hard costs of wet-lab experiments as milestones are reached and funded. - The transaction is expected to total $1.5 million in cash and in-kind contributions through completion of project milestones, target validation, and lead-candidate work.
Between the lines: - DiaGen is using a large real-world tumor dataset to train and de-risk its AI-driven discovery workflow, which is central to its pitch in biotech. - DataMeds is trying to monetize Helomics’ lab and biobank assets while expanding oncology relationships tied to its ChemoFx assay. - The partnership also gives both companies a way to create new intellectual property before seeking outside commercialization partners. - Forward-looking statements in the release make clear the program depends on milestones, continued funding and whether any target or drug candidate proves viable.
What's next: - The companies will begin therapeutic target discovery and peptide validation in breast cancer, including triple negative breast cancer. - The program may expand into additional cancer types if the initial work identifies a relevant mechanism of action. - DiaGen and Helomics will continue preclinical validation, with the goal of reaching a lead therapeutic candidate with animal proof of concept. - The companies say they plan to pursue pharma partnerships or a joint venture if the research produces promising targets or candidates.
The bottom line: - The deal pairs AI drug discovery with a large tumor biobank, and both sides are betting that better biological data will produce more valuable cancer targets and new therapeutics.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Cyprus Healthcare Press
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.